1. Industrials

  2. •

    Aerospace & Defense
Orbital ATK, Inc.

Orbital ATK, Inc.

OA
Orbital ATK, Inc.US flagNew York Stock Exchange
134.50
USD
+0.01
- -
Orbital ATK, Inc.
OA
(New York Stock Exchange)

Recent

price

134.50

P/E

ratio

- -

div

yld

- -

ROIC.AI

2003
2004
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2016
2017
TTM
FRC
56.8
61.52
74.62
87.58
105.21
126.71
140.03
146.35
145.52
140.49
134.44
150.77
89.49
88.94
77.5
82.58
87.3
Revenue per Share
3.25
4.22
4.09
4.19
5.43
6.75
4.74
8.48
9.41
7.99
8.38
10.76
5.71
5.57
5.08
5.37
6.02
Basic EPS, GAAP
3.72
3.15
3.55
4.12
-1.08
8.57
12.98
5.9
12.65
11.33
8.43
12.25
8.78
8.89
9.03
9.01
5.56
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
0.2
0.81
0.93
1.11
1.16
1.17
1.22
1.28
1.29
Dividend per Share
12.01
16.16
20.65
25.29
32.85
39.98
44.95
51.73
60.29
68.2
76.55
88.08
32.73
- -
22.04
26.05
23.37
Book Value per Share
-16.84
-21.62
-12.47
-17.58
-17.86
-18.08
-17.75
-11.46
-2.57
-0.45
8.04
-18.08
-7.13
- -
-1.97
2.63
-0.02
Tangible Book Value per Share
38
38
38
37
34
33
33
33
33
33
32
32
35
35
57
58
57
Basic Weighted Avg Shares
2,172
2,366
2,801
3,217
3,565
4,172
4,583
4,808
4,842
4,618
4,362
4,775
3,174
3,113
4,455
4,764
4,991
Sales/Revenue/Turnover
12.69
11.71
10.17
10.17
9.53
10.32
10.76
11.45
10.86
10.73
10.77
12.36
8.39
7.16
100
100
35.36
Operating Margin (%)
67
70
84
84
80
81
86
120
111
109
106
118
85
82
159
155
149
Depreciation Expense
124
162
154
154
184
222
155
279
313
263
272
341
202
195
292
310
344
Net Income, GAAP
39
25.27
30.18
32.2
30.29
36.43
51.76
35.94
28.49
35.33
30.64
33.19
33.53
34.58
28
33
29.81
Effective Tax Rate (%)
5.72
6.86
5.48
4.78
5.16
5.33
3.38
5.8
6.47
5.69
6.23
7.14
6.38
6.26
6.56
6.5
6.9
Profit Margin (%)
284
377
402
349
526
617
571
927
996
1,090
1,312
1,331
1,292
- -
893
1,082
880
Working Capital
821
1,076
1,131
1,096
1,455
1,455
1,161
1,380
1,290
1,272
1,024
1,844
1,529
- -
1,398
1,361
1,411
LT Debt
478
564
686
636
558
750
615
807
1,166
1,237
1,513
1,922
1,788
- -
1,817
2,045
1,885
Total Equity
12.3
14.05
11.47
12.15
12.34
12.98
11.13
16.46
15.06
12.05
12.72
11.97
4.79
8.65
197.1
94.91
36.85
Return on Invested Capital (%)
9.98
10.84
8.47
7.6
7.83
8.3
6.5
10.89
11.16
8.91
8.9
9.32
5.29
14.13
21.52
10.98
12.23
Return on Capital (%)
31.31
30.04
21.99
18.06
18.04
18.31
11.13
17.58
16.9
12.36
11.5
12.93
10.25
33.6
46.12
22.35
25.97
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'17
Dec'17
Mar'18
ST Debt
40
40
40
LT Borrowings
1,370
1,361
1,411
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
58
58
58
Market Capitalization
7,574
7,504
7,563

Working Capital

FRC

•

in mil. unless spec.
Sep'17
Dec'17
Mar'18
Total Current Assets
2,415
2,542
2,182
Cash, Cash Equivalents & STI
119
346
59
Accounts Receivable, Net
1,939
250
338
Inventories
267
221
248
Total Current Liabilities
1,293
1,460
1,302
Payables & Accruals
141
333
173
ST Debt
40
40
40
Deferred Revenue
274
330
271

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
12.55%
Free Cash Flow
16.46%
17.8%
0.19%
Net Income, GAAP
8.6%
7.38%
5.92%
Sales/Revenue/Turnover
2.94%
4.81%
6.93%
Total Cash Common Dividend
- -
22.03%
5.71%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2016
1,083
1,044
1,272
- -
4,455
2017
1,085
1,115
1,216
1,348
4,764
2018
1,312
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2016
1.56
1.04
1.08
- -
5.08
2017
1.15
1.54
1.65
1.06
5.37
2018
1.77
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2016
0.3
0.3
0.3
- -
1.22
2017
0.31
0.33
0.32
0.33
1.28
2018
0.32
- -
- -
- -
- -
Similar Companies
KLX Inc. (KLXI)
Hensoldt AG (HAGHY)
Byrna Technologies Inc. (BYRN)
SAM Engineering & Equipment (M) Berhad (9822.KL)
Rolls-Royce Holdings plc (RRU.DE)
Jiangxi Hongdu Aviation Industry Co., Ltd. (600316.SS)
Business
Orbital ATK Inc. (NYSE:OA) operates as an independent aerospace and defense manufacturer following its formation in 2015 from the merger of Orbital Sciences Corporation, founded in 1982, and Alliant Techsystems' aerospace and defense units; the company is headquartered in Dulles, Virginia. It designs, builds, and delivers a broad portfolio of products and services including launch vehicles such as Antares, Minotaur series, Pegasus, and the planned OmegA; solid rocket engines and boosters like GEM-40/60/63 series, Castor family, and Space Launch System boosters; satellites and spacecraft encompassing Cygnus cargo resupply vehicles for the International Space Station, communications satellites such as Al Yah 3 and HYLAS-4, and science missions including TESS, ICESat-2, and JPSS-2; tactical missiles, precision-guided munitions, ammunition, autocannons, firearms like the XM25 CDTE, and defense electronics including missile approach warning systems; as well as aerostructures, propulsion systems, and technical services for government, military, commercial, and scientific customers primarily in the United States with global operations. In a major strategic development, Northrop Grumman announced its $9.2 billion acquisition of Orbital ATK in September 2017, which closed on June 6, 2018, leading to the rebranding as Northrop Grumman Innovation Systems—a new business sector—before a 2020 reorganization integrated most operations into Northrop Grumman's Space Systems sector headquartered in McLean, Virginia; the company continues active trading under ticker OA with recent quarterly earnings reflecting EPS of $1.75 and revenue growth, alongside ongoing contributions to missile defense, space exploration, and aviation programs.

Company News

APIChat

  • gurufocus.com

    Eli Lilly's Retatrutide Shows Promising Results in Obesity and Osteoarthritis Trial

  • businesswire.com

    Zoetis Receives European Commission Marketing Authorization for Lenivia® (izenivetmab) to Reduce Pain Associated with Osteoarthritis (OA) in Dogs

  • businesswire.com

    Zoetis Announces Health Canada Approval of Lenivia® (izenivetmab injection) for Alleviation of Osteoarthritis (OA) Pain in Dogs

  • businesswire.com

    Zoetis Receives Positive Opinion from CVMP for Lenivia® (izenivetmab) to Reduce Pain Associated with Osteoarthritis (OA) in Dogs

  • businesswire.com

    Zoetis Announces U.S. FDA Approval of Librela™ (bedinvetmab injection) to Control Osteoarthritis (OA) Pain in Dogs